Improving hair loss in individuals with darker skin using a laser treatment
Official title: Clinical Study to Evaluate the Improvement in Hair Loss in Skin of Color Treated With Fractional Non-Ablative Laser
Run by Lumenis Be Ltd. · NCT06885112 · Data updated 2026-11-12
This study is testing a laser treatment to see if it can help people with darker skin who have moderate hair loss feel better about their hair.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years to 55 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Lumenis Be Ltd. Industry-sponsored |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | February 21, 2025 |
| Main results expected | February 21, 2027 |
| Study ends | February 21, 2027 |
| Registry record updated | January 2, 2026 |
| Trial ID | NCT06885112 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are healthy males and females aged 21 to 55 with Fitzpatrick skin types V or VI and mild to moderate hair loss.
✕Probably not a fit
Patients with hair loss conditions outside the specified criteria or those who have previously received similar treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical study evaluates the effectiveness of FoLix treatment, a fractional non-ablative laser therapy, in improving hair appearance in individuals aged 21 to 55 with moderate hair loss and Fitzpatrick skin types V or VI. Participants must have experienced hair thinning for over six months but less than five years and will be monitored throughout the treatment process. The study aims to assess the safety and efficacy of this intervention specifically for those with darker skin tones, which are often underrepresented in hair loss treatments.
Why it matters
Potential benefit: If successful, this treatment could provide a new effective option for individuals with darker skin experiencing hair loss.
How similar studies have gone: While there is limited data on similar approaches specifically for darker skin types, the use of fractional non-ablative lasers has shown promise in other populations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and females between 21 - 55 years of age, inclusive. * Have Fitzpatrick Skin Type V to VI. * Have mild to moderate hair loss (Ludwig scale I-II for women, Norwood-Hamilton scale I-III for males) * Have self-reported thinning or hair loss for more than 6 months prior to screening but less than 5 years. * Clinically confirmed to have hair loss or thinning by the investigator via physical exam * Didn't receive hair-loss treatments or participated in a clinical study using 1565 NAFL device * In good general health, as determined by the Investigator * Willing and able to attend all study visits * Willing to maintain the same hair style as at the Screening Visit for the duration of the study. If coloring hair, willing to color it with the same frequency of usage as in the past, making sure not to color within 1-week before and 1-week after an in-office appointment * Willing to use a mild non-medicated shampoo and conditioner for the duration of the study (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth) * Have a negative urine pregnancy test at screening and be using, and continue to use for the duration of the study, an effective contraception method (i.e., abstinence, barrier control, intrauterine device \[IUD\], or hormonal \[estrogen/progestin\] contraceptives) for at least one menstrual cycle prior to study; if using IUD or hormonal contraceptives - then at least 2 years prior to screening, the initiation of which should not have been associated with initiation of hair loss/thinning. * Be willing and able to cooperate with the requirements of the study including images taken using a smart camera (multi-spectral) of several skin conditions * Voluntarily sign and date an informed consent agreement approved by the Institutional Review Board * Be able to complete and understand the various rating instruments in English * Sponsor approved global image assessment of degree of thinning / hair loss Exclusion Criteria: * Clinical diagnosis of alopecia areata or scarring forms of alopecia * Patient is of skin type I-IV * Scalp hair loss on the treatment area, due to disease, injury, or medical therapy * Subjects who are pregnant, planning to become pregnant or breastfeeding. A urine pregnancy test will be done to rule out pregnancy. Subjects of childbearing potential who are not using an approved method of birth control (oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence). Females of non-childbearing potential are defined as postmenopausal (e.g.: absence of menstrual bleeding for one year), hysterectomy or bilateral oophorectomy * Current skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun damage, seborrheic dermatitis), cuts and or abrasions on the scalp or condition (e.g., sunburn, tattoos) on the treatment area that, in the opinion of the Investigator, might put the subject at risk or interfere with the study conduct or evaluations * Participated in a previous 1565 NAFL study or treatment * History of surgical correction of hair loss on the scalp/ Hair transplants. * Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 90 days prior to the Baseline Visit. * Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, cimetidine) within 60 days prior to the Baseline Visit. * No history of burning, flaking, itching, and stinging of the scalp. * A chronic condition of high severity dandruff. * History of malignancy (except scc and bcc skin cancers) or undergoing chemotherapy or radiation treatments. * A known history of autoimmune thyroid disease, any other thyroid disorder/abnormality or other autoimmune disorders that in the opinion of the investigator may interfere with the study treatment. * A known history of untreated or uncontrolled depression or bipolar disease or any other condition that may impact the subject's participation. * Recent utilization of low level lasers for treating hair loss (past 6 months). * Has any condition that the treating investigator or PI thinks may put the Subject at risk or interfere with their participation in the study. * Is involved in any injury litigation claims. * Known history or recent bloodwork indicating iron deficiency (ferritin level is less than 30 ng/mL), bleeding disorders or platelet dysfunction syndrome as well as subjects receiving anticoagulant therapy or smokers with usage \>20 cigarettes/day. * Use of any medications that are known to potentially cause hair loss or affect hair growth, as determined by PI.
Where it's running
-
UnionDerm
New York, New York, United States Recruiting
Study contacts
- Study coordinator: Keren Hayut
- Email: keren.hayut@lumenis.com
- Phone: +972506905252
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dual treatment with KeraFactor and Revian LED for female pattern hair loss
This study tests whether using a scalp-stimulating serum together with a Revian LED cap helps women with androgenic alopecia grow more hair than each treatment alone or placebo.
-
Scalp hair chemical changes in people with severe obesity and after bariatric surgery
This project will see if chemicals trapped in scalp hair change with body weight and can signal hair thinning or muscle loss in adults having bariatric surgery.
-
Registry for systemic treatments of alopecia areata
This study is trying to see how well different systemic treatments work for people with moderate-to-severe alopecia areata, alopecia totalis, and alopecia universalis.
-
Collecting blood samples for lab analysis
This study is testing whether blood samples taken from a finger prick can be just as good as traditional blood draws from a vein for helping with medical tests, making it easier and less stressful for patients.
-
Portable scalp cooling system to prevent hair loss during chemotherapy
This study is testing if a portable cooling device can help women with early-stage breast cancer keep their hair while undergoing chemotherapy.
-
Treatment for hair loss and skin rejuvenation using fat-derived cells
This study is testing a new treatment using fat cells to see if it can help people with hair loss and improve their skin's appearance.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.